JPWO2021098769A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021098769A5
JPWO2021098769A5 JP2022524592A JP2022524592A JPWO2021098769A5 JP WO2021098769 A5 JPWO2021098769 A5 JP WO2021098769A5 JP 2022524592 A JP2022524592 A JP 2022524592A JP 2022524592 A JP2022524592 A JP 2022524592A JP WO2021098769 A5 JPWO2021098769 A5 JP WO2021098769A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
combination product
pharmaceutical combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022524592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503229A5 (https=
JP2023503229A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/130059 external-priority patent/WO2021098769A1/en
Publication of JP2023503229A publication Critical patent/JP2023503229A/ja
Publication of JPWO2021098769A5 publication Critical patent/JPWO2021098769A5/ja
Publication of JP2023503229A5 publication Critical patent/JP2023503229A5/ja
Pending legal-status Critical Current

Links

JP2022524592A 2019-11-21 2020-11-19 抗ox40抗体とマルチキナーゼ阻害剤とによる癌の治療 Pending JP2023503229A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/120054 2019-11-21
CN2019120054 2019-11-21
PCT/CN2020/130059 WO2021098769A1 (en) 2019-11-21 2020-11-19 Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2023503229A JP2023503229A (ja) 2023-01-27
JPWO2021098769A5 true JPWO2021098769A5 (https=) 2023-11-29
JP2023503229A5 JP2023503229A5 (https=) 2023-11-29

Family

ID=75981033

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524592A Pending JP2023503229A (ja) 2019-11-21 2020-11-19 抗ox40抗体とマルチキナーゼ阻害剤とによる癌の治療

Country Status (5)

Country Link
US (1) US20230022859A1 (https=)
EP (1) EP4061421A4 (https=)
JP (1) JP2023503229A (https=)
CN (1) CN114728063B (https=)
WO (1) WO2021098769A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566935B (zh) 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法
WO2023155777A1 (en) * 2022-02-15 2023-08-24 Beigene (Suzhou) Co., Ltd. N- [ (6-bromopyridin-3-yl) methyl] -2-methoxyethan-1-amine salts and preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0816064B8 (pt) * 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
CN102010407A (zh) * 2010-11-16 2011-04-13 上海科胜药物研发有限公司 一种合成达沙替尼的新方法
SMT201800503T1 (it) * 2013-03-18 2018-11-09 Janssen Pharmaceuticals Inc Anticorpi anti-cd (ox40) umanizzati e loro usi
KR20180011839A (ko) * 2015-06-08 2018-02-02 제넨테크, 인크. 항-ox40 항체를 이용한 암의 치료 방법
GB201519481D0 (en) * 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
CN111542544A (zh) * 2017-11-01 2020-08-14 百时美施贵宝公司 用于治疗癌症的免疫刺激性激动性抗体
MX2020012081A (es) * 2018-05-11 2021-04-28 Wuxi Biologics Shanghai Co Ltd Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso.
CN112566935B (zh) * 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法

Similar Documents

Publication Publication Date Title
JP2024020298A5 (https=)
JP2020528750A5 (https=)
CN111278861A (zh) Pd-l1抗体、其抗原结合片段及医药用途
IL276695A (en) Antibodies, pharmaceutical compositions and uses thereof
JP2020019787A5 (https=)
JP2019107018A5 (https=)
IL276830B2 (en) Anti-claudin 18.2 antibodies and uses thereof
JP2017512759A5 (https=)
JP2019535254A5 (ja) 抗pd−l1抗体および変異型
JP2008531576A5 (https=)
JP2020514310A5 (https=)
HRP20151019T1 (hr) PROTUTIJELA PROTIV c-MET
JP2015535828A5 (https=)
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
JP2017510559A5 (https=)
JP2020507571A5 (https=)
JP2010535713A5 (https=)
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
JP2020522280A5 (https=)
JP2025038088A5 (https=)
JP2020522281A5 (https=)
JP2021531255A5 (https=)
JP2020505075A5 (https=)
JP2021512652A5 (https=)